Get the Stockscreener App
11.08
0.91%
0.10
After Hours:
11.10
0.02
+0.18%
Indivior Plc stock is traded at $11.08, with a volume of 488.39K.
It is up +0.91% in the last 24 hours and up +14.34% over the past month.
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
See More
Previous Close:
$10.98
Open:
$11.18
24h Volume:
488.39K
Relative Volume:
0.43
Market Cap:
$1.49B
Revenue:
$1.12B
Net Income/Loss:
$5.00M
P/E Ratio:
1,108.00
EPS:
0.01
Net Cash Flow:
$-383.00M
1W Performance:
-7.51%
1M Performance:
+14.34%
6M Performance:
+8.10%
1Y Performance:
-38.00%
1-Day Range:
$10.95
$11.30
1-Week Range:
$10.91
$12.26
52-Week Range:
$7.33
$18.59
Indivior Plc Stock (INDV) Company Profile
Name
Indivior Plc
Sector
Phone
804-379-1090
Address
234 BATH ROAD, SLOUGH, BERKSHIRE
Compare INDV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Plc
|
11.08 | 1.49B | 1.12B | 5.00M | -383.00M | 0.01 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Indivior Plc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
Indivior Plc Stock (INDV) Latest News
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Indivior PLC (INDV) - ACCESS Newswire
Indivior PLC Announces AGM Results with Key Resolutions Passed - TipRanks
Indivior PLC Sued for Securities Law ViolationsContact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights – INDV - ACCESS Newswire
Indivior PLC announces leadership and bylaw changes - Investing.com Australia
Indivior PLC announces leadership and bylaw changes By Investing.com - Investing.com Nigeria
Indivior PLC Announces Successful AGM Resolutions - TipRanks
Naloxone Market Set to Witness Significant Growth by 2025-2032 | - openPR.com
Investors who lost money on Indivior PLC (INDV) should contact Levi & Korsinsky about pending Class ActionINDV - ACCESS Newswire
Decoding Indivior PLC (INDV): A Strategic SWOT Insight - GuruFocus
Shareholders that lost money on Indivior PLC (INDV) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
When (INDV) Moves Investors should Listen - news.stocktradersdaily.com
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy - The Malaysian Reserve
INDIVIOR PLC SEC 10-Q Report - TradingView
Indivior PLC Announces Total Voting Rights and Share Capital Update - TipRanks
Opioid Antagonist Market Is Booming Worldwide 2025-2032 | - openPR.com
Drug Detoxification Market Is Booming Worldwide 2025-2032 | - openPR.com
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.
Indivior: Trying To Break Addiction (NASDAQ:INDV) - Seeking Alpha
Results: Indivior PLC Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Indivior PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Indivior to release Q4 and full-year 2024 results on Feb 20 - MSN
Indivior Reports Q1 2025 Results, Maintains FY Guidance Amid Market Challenges - MSN
Indivior PLC (INDV) Trading 3.9% Higher on Apr 25 - GuruFocus
Indivior Announces Q1 2025 Financial Results - The Malaysian Reserve
Indivior Faces Revenue Challenges Amid Competitive Pressures - TipRanks
Indivior Q1 2025 Earnings Call Transcript - MarketBeat
Indivior (INDV) Q1 2025 Earnings Call - Mitrade
FTSE 250 movers: Indivior surges; Inchcape slips - Sharecast.com
Indivior PLC (INDV) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Indivior PLC Q1 2025 Earnings: EPS of $0.38 Beats Estimate, Revenue Hits $266 Million - GuruFocus
Indivior Q1 2025 Financial Results - TradingView
Indivior (INDV) Surpasses Q1 Revenue Projections with $266M Repo - GuruFocus
Indivior shares surge following robust Q1 revenue and positive outlook By Investing.com - Investing.com Nigeria
Indivior Announces Q1 2025 Financial Results | INDV Stock News - GuruFocus
A Look at Indivior's Upcoming Earnings Report - Benzinga
Indo-Asian News Service-INDIVIOR ANNOUNCES Q1 2025 FINANCIAL RESULTS - Indo-Asian News Service (IANS)
In the wake of Indivior PLC's (LON:INDV) latest UK£44m market cap drop, institutional owners may be forced to take severe actions - simplywall.st
U.S. Opioid Withdrawal Treatment Market Emerging Trends - openPR.com
Indivior Plc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):